The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Immunotherapies Continue to Impress in NSCLC Trials With Several Forecast for Approval
November 10th 2014Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.
Lung Cancer Treatment on Brink of New Molecular Era
November 10th 2014Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.
Dr. Levy Discusses Recent Updates in Immunotherapy for Lung Cancer
November 10th 2014Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.
Dr. Arcila on the Benefits of New Molecular Diagnostic Platforms for the Treatment of Lung Cancer
November 10th 2014Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.
PER Conference Features Expert Views on Lung Cancer Advances
November 7th 2014Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.
New Research Focuses on Personalized Treatments in Ovarian Cancer
November 6th 2014Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.
Safra Provides an Overview of PARP Inhibitors in Ovarian Cancer
November 6th 2014PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.
Expert Critiques Adjuvant Tamoxifen Guideline for HR-Positive Breast Cancer
November 6th 2014In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.
New Vaccine Formulation Effective in Low-Grade Lymphoma
November 5th 2014The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a toll-like receptor 3 (TLR) 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma
Dr. Patel on the Benefits of a Multidisciplinary Approach for Patients With Stage III Lung Cancer
November 1st 2014Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.
Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC
November 1st 2014David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.
Nivolumab Plus Chemotherapy Shows Similar Efficacy to Nivolumab Monotherapy in NSCLC
Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.